Cargando…

Behaviours and attitudes influencing treatment decisions for menopausal symptoms in five European countries

OBJECTIVE: To assess women’s behaviours and attitudes regarding the treatment of menopausal symptoms in five European countries. STUDY DESIGN: Women aged ≥45 years in France, Germany, Italy, Spain, and the United Kingdom participated in an internet survey. Completers were those who reported menopaus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Constantine, Ginger D, Graham, Shelli, Clerinx, Cathy, Bernick, Brian A, Krassan, Mitchell, Mirkin, Sebastian, Currie, Heather
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019289/ https://www.ncbi.nlm.nih.gov/pubmed/26895640 http://dx.doi.org/10.1177/2053369116632439

Ejemplares similares

SAT-238 Predictors Of Vaginal/Uterine Bleeding With Oral TX-001HR (Estradiol and Progesterone) Capsules Taken For Menopausal Vasomotor Symptoms
por: Constantine, Ginger, et al.
Publicado: (2019)

Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence review
por: Constantine, Ginger D., et al.
Publicado: (2019)

SAT-LB003 Nonsmokers Benefit from Lower Doses of an Estradiol/Progesterone Combination: Results of the REPLENISH Trial
por: Constantine, Ginger, et al.
Publicado: (2019)

Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone
por: Mirkin, Sebastian, et al.
Publicado: (2019)

SAT-237 Combined Bioidentical Estradiol and Progesterone Capsules Improved Quality of Sleep in Postmenopausal Women with Vasomotor Symptoms
por: Santoro, Nanette, et al.
Publicado: (2019)

Prescribing of FDA-approved and compounded hormone therapy differs by specialty
por: Constantine, Ginger D., et al.
Publicado: (2016)

SAT-021 Effects of E2/P4 Oral Capsules on Bone Turnover in Women with Vasomotor Symptoms
por: Constantine, Ginger, et al.
Publicado: (2020)

17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial
por: Kaunitz, Andrew M., et al.
Publicado: (2020)

Effects of E2/P4 oral capsules on bone turnover in women with vasomotor symptoms
por: McClung, Michael R., et al.
Publicado: (2022)

The MATE survey: men's perceptions and attitudes towards menopause and their role in partners’ menopausal transition
por: Parish, Sharon J., et al.
Publicado: (2019)

Breast effects of oral, combined 17β-estradiol, and progesterone capsules in menopausal women: a randomized controlled trial
por: Liu, James H., et al.
Publicado: (2020)

Consistency of Effect with a Low-Dose, Estradiol Vaginal Capsule (TX-004HR): Evaluating Improvement in Vaginal Physiology and Moderate-to-Severe Dyspareunia in Subgroups of Postmenopausal Women
por: Constantine, Ginger D., et al.
Publicado: (2017)

Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trial
por: Simon, James A., et al.
Publicado: (2017)

Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms
por: Constantine, Ginger D., et al.
Publicado: (2019)

Patient acceptability and satisfaction with a low-dose solubilized vaginal estradiol softgel capsule, TX-004HR
por: Kingsberg, Sheryl A., et al.
Publicado: (2017)

TX-004HR vaginal estradiol has negligible to very low systemic absorption of estradiol
por: Archer, David F., et al.
Publicado: (2017)

TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial
por: Constantine, Ginger D., et al.
Publicado: (2020)

SAT-001 Clinically Meaningful Effects of E2/P4 Oral Capsule in Treating Vasomotor Symptoms
por: Constantine, Ginger, et al.
Publicado: (2020)

The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy
por: Constantine, Ginger D., et al.
Publicado: (2017)

Systemic estradiol levels with low-dose vaginal estrogens
por: Santen, Richard J., et al.
Publicado: (2019)

Improvement in sleep outcomes with a 17β-estradiol–progesterone oral capsule (TX-001HR) for postmenopausal women
por: Kagan, Risa, et al.
Publicado: (2018)

Effects of combined 17β-estradiol and progesterone on weight and blood pressure in postmenopausal women of the REPLENISH trial
por: Black, Denise R., et al.
Publicado: (2020)

Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms
por: Simon, James A., et al.
Publicado: (2019)

Pharmacokinetics of the first combination 17β-estradiol/progesterone capsule in clinical development for menopausal hormone therapy
por: Pickar, James H., et al.
Publicado: (2015)

Endometrial safety and bleeding profile of a 17β-estradiol/progesterone oral softgel capsule (TX-001HR)(∗)
por: Mirkin, Sebastian, et al.
Publicado: (2020)

Physical characteristics and properties of estradiol softgel vaginal inserts
por: Simon, James A., et al.
Publicado: (2019)

Increased Incidence of Endometrial Cancer Following the Women's Health Initiative: An Assessment of Risk Factors
por: Constantine, Ginger D., et al.
Publicado: (2019)

Evaluation of endometrial progesterone receptor expression after 12 weeks of exposure to a low-dose vaginal estradiol insert
por: Mirkin, Sebastian, et al.
Publicado: (2021)

Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules)
por: Lobo, Rogerio A., et al.
Publicado: (2019)

Compounded non-FDA–approved menopausal hormone therapy prescriptions have increased: results of a pharmacy survey
por: Pinkerton, JoAnn V., et al.
Publicado: (2016)

Incorporating bazedoxifene/conjugated estrogens into the current paradigm of menopausal therapy
por: Komm, Barry S, et al.
Publicado: (2012)

WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history
por: Kingsberg, Sheryl A., et al.
Publicado: (2019)

The Tissue Selective Estrogen Complex: A Promising New Menopausal Therapy
por: Komm, Barry S., et al.
Publicado: (2012)

Management of osteoporosis and menopausal symptoms: focus on bazedoxifene/conjugated estrogen combination
por: Mirkin, Sebastian, et al.
Publicado: (2013)

Evaluation of the Effectiveness of Health Education on Menopause Symptoms and Knowledge and Attitude in Terms of Menopause
por: Koyuncu, Tugce, et al.
Publicado: (2018)

Menopause knowledge and attitude among Iranian women
por: Taherpour, M, et al.
Publicado: (2015)

Changes in Eating Behaviour during SARS-CoV-2 Pandemic among the Inhabitants of Five European Countries
por: Górska, Paulina, et al.
Publicado: (2021)

The primary drivers of private-sphere pro-environmental behaviour in five European countries during the Covid-19 pandemic
por: Iwińska, Katarzyna, et al.
Publicado: (2023)

Investigating the relationship between menopausal women's health anxiety and sexual performance and attitude towards menopause
por: Malaijerdi, Raziyeh, et al.
Publicado: (2023)

Pharmacokinetic studies of solubilized estradiol given vaginally in a novel softgel capsule
por: Pickar, J. H., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_jgtq95vcb2f2pmnb6a385shubn